Clinical Trials Browser

Phase 3 × avelumab × Clear all

NCT05092958 2026-03-18

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03815643 2025-12-04

Avelumab Program Rollover Study

Phase 3 Active not recruiting

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT03271372 2025-09-17

ADAM

Phase 3 Active not recruiting

Carcinoma, Merkel Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT05059522 2025-06-25

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT02999087 2025-05-07

REACH

Phase 3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3 Completed

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04637594 2025-01-15

IMAGINE

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Phase 3 Completed

566 enrolled 40 charts

Ovarian Neoplasms

NCT03827044 2022-10-07

POLEM

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms, Microsatellite Instability

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase 3 Completed

499 enrolled 22 charts

Neoplasm Metastasis, Neoplasms

NCT02952586 2021-09-22

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Phase 3 Terminated

697 enrolled 26 charts

Squamous Cell Carcinoma of Head and Neck

NCT02951156 2020-12-17

Javelin DLBCL

Phase 3 Terminated

29 enrolled 24 charts

Lymphoma, Large B-Cell, Diffuse

NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase 3 Completed

371 enrolled 18 charts

Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02395172 2020-08-03

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Phase 3 Completed

792 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT02718417 2020-07-14

JAVELIN OVARIAN 100

Phase 3 Terminated

998 enrolled 39 charts

Ovarian Neoplasms